AngioDynamics Q3 net sales $74.0M (+3.9% YoY); GAAP EPS -$0.13, adjusted $0.03; reaffirms FY guidance

ANGIODYNAMICS INC

2022-Q3 EPS reported -$0.52 revenue$229,221,000

Net sales $74.0M (+3.9% YoY); Med Tech +28.6% driven by Auryon ($7.3M) and thrombectomy; Med Device -2.8%.
Gross margin 52.2%, down 190bps YoY on inflation, labor, supply chain; net loss $5.0M ($0.13/sh) vs $3.5M loss prior year.
Adjusted EPS $0.03 (incl. $4.2M CARES Act benefit); adjusted EBITDA $6.7M vs $5.4M a year ago.
Reaffirmed FY2022 guidance: sales $310-315M, gross margin 52-54%, adjusted EPS -$0.02 to $0.02.
Post-quarter: FDA cleared AlphaVac F18 for venous use; IDE approved for pulmonary embolism; PRESERVE prostate trial enrolled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.